Страна: Австралия
Язык: английский
Источник: Department of Health (Therapeutic Goods Administration)
oxycodone hydrochloride, Quantity: 5 mg; naloxone hydrochloride dihydrate, Quantity: 2.73 mg (Equivalent: naloxone hydrochloride?, Qty 2.5 mg)
Mundipharma Pty Ltd
Tablet, modified release
Excipient Ingredients: ethylcellulose; macrogol 3350; brilliant blue FCF aluminium lake; stearyl alcohol; polyvinyl alcohol; titanium dioxide; magnesium stearate; lactose monohydrate; purified talc; hyprolose
Oral
20, 60, 28
(S8) Controlled Drug
MPL-Oxycodone/Naloxone modified release tablets are indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and ,- requires daily, continuous, long term treatment.,MPL-Oxycodone/Naloxone modified release tablets are not indicated for use in chronic noncancer pain other than in exceptional circumstances.,MPL-Oxycodone/Naloxone modified release tablets are not indicated as an as-needed (PRN) analgesia.,The naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,MPL-Oxycodone/Naloxone is indicated as second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.
Visual Identification: blue, oblong tablets marked "OXN" on one side and "5" on other; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2022-10-17